Skip to main content
GT Biopharma, Inc. logo

GT Biopharma, Inc. — Investor Relations & Filings

Ticker · GTBP ISIN · US36254L2097 US Professional, scientific and technical activities
Open in API
Filings indexed 862 across all filing types
Latest filing 2026-05-22 Delisting Announcement
Country US United States of America
Listing US GTBP

About GT Biopharma, Inc.

https://www.gtbiopharma.com/

GT Biopharma, Inc. is a clinical-stage immuno-oncology company focused on developing innovative therapies based on its proprietary NK cell engager (TriKE®) technology. The TriKE® platform generates therapeutic agents that are designed to simultaneously bind to Natural Killer (NK) cells and cancer cells. This targeted engagement activates and directs the cytotoxic function of NK cells to selectively destroy malignant cells. The company's pipeline targets a range of hematologic malignancies and solid tumors, including acute myeloid leukemia, myeloid dysplastic syndrome, and non-Hodgkin's lymphoma.

Recent filings

Filing Released Lang Actions
8-K
Delisting Announcement Classification · 98% confidence The document is a Form 8-K current report under Item 3.01 (“Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard”). It details Nasdaq’s notification and compliance period for the company’s failure to maintain the minimum bid price, which is exactly a delisting-related announcement. Thus, it fits the “Delisting Announcement” category.
2026-05-22 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
Regulatory Filings 2026
Regulatory Filings
2026-05-14 English
424B3 - GT Biopharma, Inc. (0000109657) (Filer)
Share Issue/Capital Change Classification · 75% confidence The document is a Form 424B3 prospectus filed under Rule 424(b)(3) with the SEC, detailing the registration of up to 9,723,057 shares of common stock for sale by selling stockholders. It is not a management change notice, earnings release, annual report, or other specific category. Instead, it describes an offering/registration of shares (including issuance upon conversion of preferred, exercise of warrants, dividends, etc.), which falls under “Share Issue/Capital Change.”
2026-05-13 English
S-1
Regulatory Filings Classification · 91% confidence The document is a Form S-1 registration statement (“Registration Statement under the Securities Act of 1933”) including a preliminary prospectus for a shelf offering. This is a detailed SEC filing for registration of shares, not an earnings release, annual report, proxy, or any other category defined. As there is no specific code for Form S-1 filings, it falls under the fallback category of general regulatory/compliance filings. Therefore, the correct classification is Regulatory Filings (RNS).
2026-04-30 English
8-K - GT Biopharma, Inc. (0000109657) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 3, 2026. It reports the entry into a material definitive agreement related to a clinical trial agreement with the University of Minnesota. The document includes a description of the agreement and references an exhibit containing the full agreement text. There are no financial statements or quarterly/yearly financial results presented. The document is not an annual report, earnings release, or interim report. It is a regulatory filing to disclose a material event (entry into a material definitive agreement). Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 5718 characters, which is sufficient for a substantive filing but it is clearly a Form 8-K current report, which falls under Regulatory Filings.
2026-04-07 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.